Sector News

Nicholas Valeriani Appointed To Edwards Lifesciences’ Board Of Directors

November 17, 2014
Life sciences
Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that Nicholas J. Valeriani has been appointed to its board of directors and will also serve as a member of its Compensation and Governance Committee.  Since 2012, Valeriani, 58, has been the Chief Executive Officer of the Gary and Mary West Health Institute, an independent, nonprofit medical research organization that works to create new, more effective ways of delivering care at lower costs.  Prior to joining West Health, Valeriani spent 34 years at Johnson & Johnson and served as a member of its executive committee. 
 
“We are pleased to add Nick’s talents and deep experience to a strong board that is guiding Edwards’ focused innovation strategy, as we develop and deliver important therapies to patients in need,” said Michael A. Mussallem, Edwards’ chairman and CEO. “I’m confident that his long career dedicated to improving patients’ lives provides him with a very informed and contemporary view on both the development of groundbreaking devices and also how best to provide them to patients and physicians in an increasingly complex global healthcare system.”
 
Currently, Valeriani serves on the boards of directors of Robert Wood Johnson University Hospital, the Reagan-Udall Foundation, Reflexion Health, Inc., and the Center for Medical Interoperability.
 
Valeriani has a master’s degree in business administration from Rutgers University, Graduate School of Management, and a bachelor’s degree in industrial engineering from Rutgers University, College of Engineering.
 
Source: Edwards Lifesciences

3 responses to “Nicholas Valeriani Appointed To Edwards Lifesciences’ Board Of Directors

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

January 23, 2021

Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m

Life sciences

Thermo Fisher Scientific has acquired Novasep’s viral vector manufacturing business in Belgium, Henogen, for about €725m ($874.5m) in cash. Henogen offers biotechnology firms, as well as biopharma customers contract manufacturing services for vaccines and therapies.

January 23, 2021

Lilly and Merus partner to develop T-Cell re-directing antibody therapies

Life sciences

Research and development group of Eli Lilly and Company, Loxo Oncology at Lilly, and clinical-stage oncology company Merus have announced a research collaboration and exclusive license agreement to develop T-Cell re-directing bispecific antibodies.

January 23, 2021

Adagene plans $125M IPO to go after cancer niches targeted by BMS and Pfizer

Life sciences

Chinese cancer biotech Adagene has filed to raise up to $125 million in a Nasdaq IPO. The listing will give Adagene the means to run early-phase clinical trials of antibodies against CD137 and CTLA-4.

Send this to a friend